Treatment of inverse psoriasis with efalizumab
George, D.; Rosen, T.
Journal of Drugs in Dermatology Jdd 8(1): 74-76
2009
ISSN/ISBN: 1545-9616 PMID: 19180901 Document Number: 15806
Various topical and systemic treatments have shown efficacy in plaque and palmoplantar psoriasis; however, studies regarding efficacy in inverse psoriasis are few. The authors present a case of a patient with severe inverse psoriasis who was successfully treated with efalizumab, resulting in complete and sustained remission during prolonged maintenance therapy.
Document emailed within 1 workday
Related Documents
Golda, N.; Benham, S.M.; Koo, J. 2006: Rebound of psoriasis during treatment with efalizumab Journal of Drugs in Dermatology: Jdd 5(1): 63-65Lamerson, C.; Stevens, G.; Sax, K. 2008: Treatment of nail psoriasis with efalizumab: a preliminary study Cutis 82(3): 217-220
Fretzin, S.; Crowley, J.; Jones, L.; Young, M.; Sobell, J. 2006: Successful treatment of hand and foot psoriasis with efalizumab therapy Journal of Drugs in Dermatology: Jdd 5(9): 838-846
Kircik, L.H.; Liu, C.; Goffe, B.S. 2008: Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy Journal of Drugs in Dermatology: Jdd 7(10): 947-952
Gaylor, M.-L.N.; Duvic, M. 2004: Generalized pustular psoriasis following withdrawal of efalizumab Journal of Drugs in Dermatology: Jdd 3(1): 77-79
Maskatia, Z.K.; Koo, J. 2007: Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine Journal of Drugs in Dermatology: Jdd 6(9): 941-944
Gadzia, J.; Turner, J. 2010: Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab Journal of Drugs in Dermatology: Jdd 9(8): 1005-1009
Fernandez-Obregon, A.C. 2008: Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo Journal of Drugs in Dermatology: Jdd 7(7): 679-681
Weinberg, J.M.; Saini, R.; Tutrone, W.D. 2002: Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept Journal of Drugs in Dermatology: Jdd 1(3): 303-310
Tutrone, W.D.; Saini, R.; Weinberg, J.M. 2004: Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept Idrugs: the Investigational Drugs Journal 7(1): 45-49
Cassano, N.; Miracapillo, A.; Buquicchio, R.; Mastrandrea, V.; Vena, G.A. 2008: Safe use of efalizumab in a psoriasis patient with chronic heart failure due to hypertrophic cardiomyopathy Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale Societa Italiana di Dermatologia e Sifilografia 143(2): 167
Gottlieb, A.B.; Gordon, K.B.; Lebwohl, M.G.; Caro, I.; Walicke, P.A.; Li, N.; Leonardi, C.L. 2004: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis Journal of Drugs in Dermatology: Jdd 3(6): 614-624
Wang, G.; Li, C.; Gao, T.; Liu, Y. 2005: Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study European Journal of Dermatology: Ejd 15(3): 176-178
Weinberg, J.M.; Bottino, C.J.; Lindholm, J.; Buchholz, R. 2005: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept Journal of Drugs in Dermatology: Jdd 4(5): 544-555
Farshidi, A.; Sadeghi, P. 2006: Successful treatment of severe refractory atopic dermatitis with efalizumab Journal of Drugs in Dermatology: Jdd 5(10): 994-998
Chowaniec, O.; Blichowska, T. 1979: Case of generalized pustular psoriasis caused by corticosteroid treatment of simple psoriasis and pemphigus Przeglad Dermatologiczny 66(5): 541-544
Wong, J.W.; Kamangar, F.; Nguyen, T.V.; Koo, J.Y.M. 2012: Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm Skin Therapy Letter 17(5): 6-9
Au, S-Chung.; Madani, A.; Alhaddad, M.; Alkofide, M.; Gottlieb, A.B. 2013: Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center Journal of drugs in dermatology: JDD 12(8): 861-866
Balevi, A.; Olmuşçelik, O.; Ustuner, P.; Özdemir, M. 2018: Is there any Correlation between Red Cell Distribution Width, Mean Platelet Volume Neutrophil Count, Lymphocyte Count, and Psoriasis Area Severity Index in Patients Under Treatment for Psoriasis? Acta Dermatovenerologica Croatica: Adc 26(3): 199-205
Hernandez Garcia, I. 2008: Severe erythroderma in a patient under intermittent therapy with efalizumab Journal of Drugs in Dermatology: Jdd 7(10): 987-989